Komori

Earnings Presentation for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027

Results presentationFirst half, FY ending Mar 2027Published 2026-11-13 15:30

In the interim period, firm sales led revenue, operating profit and ordinary profit to exceed the year-earlier levels, while interim net income declined sharply due to an impairment loss associated with the cancellation of development of a new core system. The full-year forecasts for revenue and net income were revised downward, while the forecasts for operating profit, ordinary profit and the annual dividend were left unchanged.

Contents of this document

Financial results presentationFiscal year ending March 2027, second quarter (interim period)5 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥19,512 million+5.5%
Operating profit¥2,388 million+2.8%
Ordinary income¥2,546 million+6.6%
Net income¥235 million-89.4%
Operating profit margin12.2 %
Results for the three months of the current quarter
Net Sales
¥9,618 million
Operating profit
¥1,204 million
Full-year earnings forecast
Net Sales
¥41,000 million
Operating profit
¥4,700 million
Ordinary income
¥4,800 million
Profit attributable to owners of the parent
¥1,400 million
Annual Dividend
¥40
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales45.4 %
Gross profit47 %
Operating profit50.8 %
Ordinary income53.1 %
Interim net income attributable to owners of the parent9.8 %
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Although sales in Japan and other markets were below plan, operating profit remained roughly in line with the initial forecast due to improved profitability.
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Gelatin¥459 million
Collagen peptides¥454 million
Food Materials¥66 million
Biomedical¥32 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
US dollar
Revised full-year forecast for the fiscal year ending March 2027¥158.77
Canadian dollar
Revised full-year forecast for the fiscal year ending March 2027¥112.89
Indian rupee
Revised full-year forecast for the fiscal year ending March 2027¥1.66
New initiatives
  • Cancellation of development of the new core system
  • Modification and optimisation of the existing core system
  • Fundamental BPR and cost reductions at the Osaka plant
  • Promotion of digital transformation using peripheral IT technologies
  • Reduction of personnel resources and cost burdens for system development through the use of AI
Annual Dividend
Annual¥40
Contents of this document
ItemDetails
Document typeFinancial results presentation
Fiscal Period CoveredFiscal year ending March 2027, second quarter (interim period)
Net Sales¥19,512 million (YoY +5.5%)
Operating profit¥2,388 million (YoY +2.8%)
Ordinary income¥2,546 million (YoY +6.6%)
Net income¥235 million (YoY -89.4%)
Operating profit margin12.2 %
Results for the three months of the current quarterNet Sales ¥9,618 million / Operating profit ¥1,204 million
Full-year earnings forecastNet Sales ¥41,000 million / Operating profit ¥4,700 million / Ordinary income ¥4,800 million / Profit attributable to owners of the parent ¥1,400 million / Annual Dividend ¥40
Progress against full-year forecastNet Sales 45.4 % / Gross profit 47 % / Operating profit 50.8 % / Ordinary income 53.1 % / Interim net income attributable to owners of the parent 9.8 %
Self-assessment against the planAlthough sales in Japan and other markets were below plan, operating profit remained roughly in line with the initial forecast due to improved profitability.
Breakdown of Factors Affecting the ChangeGelatin ¥459 million / Collagen peptides ¥454 million / Food Materials ¥66 million / Biomedical ¥32 million
Assumptions Underlying the Business OutlookUS dollar Revised full-year forecast for the fiscal year ending March 2027 ¥158.77 / Canadian dollar Revised full-year forecast for the fiscal year ending March 2027 ¥112.89 / Indian rupee Revised full-year forecast for the fiscal year ending March 2027 ¥1.66
Annual DividendAnnual ¥40
New initiativesCancellation of development of the new core system, Modification and optimisation of the existing core system, Fundamental BPR and cost reductions at the Osaka plant, Promotion of digital transformation using peripheral IT technologies, Reduction of personnel resources and cost burdens for system development through the use of AI
Items this document does not state (16)
Gross Profit MarginSelling, general and administrative expensesSegment resultsKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

Earnings Presentation for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 | Nitta Gelatin Inc. (4977) timely disclosure | Komori